Lupus & antiphospholipid syndrome
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients
Authors' conclusion
Our study not only demonstrates belimumab's efficacy in attaining treat-to-target goals in SLE patients, but also confirms its GC-sparing effect, and its prevention of flares and organ damage accrual.
Study context
- Population
- SLE patients treated with belimumab (BLM) at 18 Spanish centersmean follow-up 3.8 (±2.7) years
- Participants
- 324 patients
- Outcome
- LLDAS and DORIS attainment on successive visits (6 months, 12 months, last visit)
Methodological detailslongitudinal, multicenter (18 Spanish centers), Data collected at BLM initiation, at 6 and 12 months, and at last recorded visit
- Longitudinal
- Multicenter (18 Spanish centers)
- Data collected at BLM initiation, at 6 and 12 months, and at last recorded visit
Main finding
As reported in the abstract
LLDAS attained, successive visits
45.8%, 62% and 71%
DORIS attained, successive visits
24%, 36.2% and 52.5%
Observational data: associations, not effects.
Further findings
Time in remission/low disease activity (DORIS ≥50% of visits; LLDAS-50)
- Patients in DORIS ≥50% of the visits
- 27.2%
- Patients in LLDAS-50
- 46%
Flares and number of flares · 1 year after BLM
- Flares and number of flares significantly lower one year after BLM
Damage accrual
- No changes in damage accrual observed
GC use
- Patients discontinuing GC
- 70 (24%)
- Mean prednisone dose significantly reduced over time
Original publication
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →